Edit Entry

Charles L. Sentman, Ph.D.

Title(s):
Professor of Microbiology and Immunology

Department(s):
Microbiology and Immunology

Education:
University of Texas Southwestern Medical Center, Ph.D. 1990
University of Illinois, B.S., 1985

Dr. Sentman did postdoctoral training at Washington University Medical School in St. Louis, MO on the role of cell death in T cell development. From 1992 to 1995, he conducted postdoctoral research at the Microbiology and Tumor Biology Center at the Karolinska Institute in Stockholm, Sweden on natural killer (NK) cell recognition mechanisms. In 1995 he joined the medical faculty and became an investigator at the Umea Center for Molecular Pathogenesis at Umea University, Umea, Sweden where he continued his research program on NK cell receptors. In 1997, Dr. Sentman received a docentur in molecular immunology from Umea University. From 1998 to 2001, Dr. Sentman worked as a team leader and section leader at AstraZeneca R&D in Lund, Sweden with the aim to develop new pharmaceuticals against respiratory and inflammation diseases, including asthma and rheumatoid arthritis. In 2001, Dr. Sentman joined the faculty of the department of Microbiology and Immunology at Dartmouth Medical School as an assistant professor.

Programs:
Molecular and Cellular Biology Graduate Programs

Websites:
http://dms.dartmouth.edu/microbio/
http://dms.dartmouth.edu/immuno/
http://www.dartmouth.edu/~mcb/

Contact Information:

Dartmouth Medical School
Borwell Research Building - HB 7556
1 Medical Center Drive
Lebanon NH 03756

Phone: 603-653-0611
Fax: 603-650-6223
Email: Charles.L.Sentman@Dartmouth.Edu


Professional Interests:

Natural killer (NK) cells are an important part of the innate immune system and have the ability to kill tumor cells and some virus-infected cells while sparing nearby normal cells. Dr. Sentman's research interests are NK cell recognition mechanisms, the role of NK cells as a part of the immune defense against cancer and infection, and how NK cell and T cell effector mechanisms affect the tumor microenvironment. His laboratory is focused on the development of novel immunotherapy strategies for cancer, and there are several major areas of research: chimeric NK cell receptor based immunotherapy, bi-specific antibody targeting of tumors using NK cell receptors, and development of novel signaling platforms for cell based therapies.

NK receptor based chimeric antigen receptors (CARs) as immunotherapy: NK cells express a number of different receptors that can recognize tumor cells, and their ligands are expressed on many different types of tumor cells making them good targets for the treatment of cancer. Dr. Sentmanís lab has developed a novel immunotherapy targeting strategy using chimeric NKG2D receptors. These NKG2D CARs are formed by a fusion of NKG2D with a cytoplasmic signaling domain of CD3zeta. However, because NKG2D is a type II protein, the orientation of CD3zeta is reversed. NKG2D recognizes several ligands that are often expressed on tumor cells but not normal tissues. Almost 90% of human cancers are of tumor types that have been shown to express ligands for NKG2D. In addition, immunosuppressive cells (MDSCs, Tregs) may also express NKG2D ligands within the tumor microenvironment. When expressed in T cells by viral transduction, these NKG2D CARs are able to recognize tumor cells in an MHC independent manner, and they trigger T cells to produce proinflammatory cytokines and kill tumor cells upon recognition of their ligands. In fact, extensive analysis in syngeneic lymphoma and ovarian cancer models has shown that both cytotoxicity and cytokines are an essential part of the CAR T cell efficacy. Dr. Sentmanís laboratory is using this approach to target ovarian cancer, lymphoma, and myeloma, and this approach has the potential to be applied to other tumors such as breast cancer, melanoma, and osteosarcoma. His laboratory is working on development and analysis of a number of other CARs based on NK cell receptors and their ligands.

Bi-specific T cell engagers: It is possible to target tumors effectively using bi-specific antibodies that trigger T cell effector function when they also bind to ligand expressing tumor cells. Dr. Sentmanís laboratory has developed a bi-specific T cell engager or BiTE based on the scFv from anti-CD3 and NKG2D. This hybrid molecule binds to T cells via CD3 and to tumor cells via NKG2D. These small bi-specific proteins lack a Fc receptor, which avoids off-tumor toxicity due to potential interaction with Fc receptor expressing cells such as macrophages or dendritic cells. Clinical data using an anti-CD19-anti-CD3 bi-specific molecule demonstrated excellent efficacy at very low doses. The potential of these bi-specific molecules is to treat cancer through activation of a patientís own T cells. Dr. Sentmanís research group is developing novel bi-specific molecules based on various NK cell receptor and their ligands, demonstrating efficacy in melanoma and lymphoma models, and investigating their mechanisms of action against different tumor types.

Novel cell based therapies: Dr. Sentmanís team is working on developing several new signaling platforms that can serve as the basis for adoptive cell therapies against cancer, autoimmunity, and infectious diseases. These platforms are designed to be used with many different recognition strategies to allow flexibility to create cell based therapies that bind to key targets and provide unique effector functions to modify local immunity.

Clinical development: Dr. Sentman is working in collaboration with Celdara Medical LLC and the Dana-Farber Cancer Center to move the NKG2D-based CAR into a Phase I clinical trial. He is also working with clinicians at Dartmouth-Hitchcock Medical Center and other collaborators to develop and move their other therapeutic ideas into clinical development. Several of these technologies have been patented or have patents pending. To inquire about licensing or collaborative opportunities, please contact Dr. Sentman or the Dartmouth Technology Transfer Office.


Selected Publications:

 

Sentman CL, Meehan KR
NKG2D CARs as Cell Therapy for Cancer.
Cancer J 2014 Mar-Apr; 20(2):156-9
PMID: 24667963

Talebian L, Fischer DA, Wu J, Channon JY, Sentman CL, Ernstoff MS, Meehan KR
The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.
Transfusion 2014 Jan 22;
PMID: 24446786

Spear P, Wu MR, Sentman ML, Sentman CL
NKG2D ligands as therapeutic targets.
Cancer Immun 2013; 13:8
PMID: 23833565

Spear P, Barber A, Sentman CL
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
Oncoimmunology 2013 Apr 1; 2(4):e23564
PMID: 23734311

Spear P, Barber A, Rynda-Apple A, Sentman CL
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Immunol Cell Biol 2013 Jul; 91(6):435-40
PMID: 23628805

Zhang T, Sentman CL
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
J Immunol 2013 Mar 1; 190(5):2455-63
PMID: 23355740

Meehan KR, Talebian L, Tosteson TD, Hill JM, Szczepiorkowski Z, Sentman CL, Ernstoff MS
Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma.
Biol Blood Marrow Transplant 2013 Jan; 19(1):129-37
PMID: 22975165

Zhang T, Wu MR, Sentman CL
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
J Immunol 2012 Sep 1; 189(5):2290-9
PMID: 22851709

Spear P, Barber A, Rynda-Apple A, Sentman CL
Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-ő≥ and GM-CSF.
J Immunol 2012 Jun 15; 188(12):6389-98
PMID: 22586039

Iyori M, Zhang T, Pantel H, Gagne BA, Sentman CL
TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of T cells.
J Immunol 2011 Sep 15; 187(6):3087-95
PMID: 21832159